Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
IPO Year: 2017
Exchange: NASDAQ
Website: athenex.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/12/2021 | $8.00 → $5.00 | Outperform | RBC Capital |
| 8/6/2021 | $9.00 → $8.00 | Outperform | RBC Capital |
| 8/6/2021 | $5.00 → $4.00 | Market Perform | SVB Leerink |
Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling
Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
4 - Athenex, Inc. (0001300699) (Issuer)
BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy. "We are delighted to welcome Dr. Cohen to Athenex during this transformative period, as we strategically pivot to focus on advancing first-in-class
BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity, investment banking, and Big4 Advisory, with over 20 years of corporate finance experience. "The Board of Directors joins me in welcoming Joe to his new position as CFO," said Johnson Lau, Chief
RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $5.00 from $8.00 previously
RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $8.00 from $9.00 previously
SVB Leerink reiterated coverage of Athenex with a rating of Market Perform and set a new price target of $4.00 from $5.00 previously
Truist Securities resumed coverage of Athenex with a rating of Hold and set a new price target of $6.00 from $29.00 previously
SVB Leerink resumed coverage of Athenex with a rating of Market Perform and set a new price target of $5.00 from $22.00 previously
JPMorgan Chase & Co. resumed coverage of Athenex with a rating of Neutral and set a new price target of $7.00 from $30.00 previously
Oppenheimer resumed coverage of Athenex with a rating of Market Perform
Royal Bank of Canada reiterated coverage of Athenex with a rating of Outperform and set a new price target of $33.00 from $9.00 previously
Oppenheimer downgraded Athenex from Outperform to Perform
Oppenheimer downgraded Athenex from Outperform to Market Perform
8-K - Athenex, Inc. (0001300699) (Filer)
8-K - Athenex, Inc. (0001300699) (Filer)
8-K - Athenex, Inc. (0001300699) (Filer)
NT 10-Q - Athenex, Inc. (0001300699) (Filer)
8-K - Athenex, Inc. (0001300699) (Filer)
8-K - Athenex, Inc. (0001300699) (Filer)
10-K/A - Athenex, Inc. (0001300699) (Filer)
8-K - Athenex, Inc. (0001300699) (Filer)
8-K - Athenex, Inc. (0001300699) (Filer)
10-K - Athenex, Inc. (0001300699) (Filer)
SC 13D/A - Athenex, Inc. (0001300699) (Subject)
SC 13D - Athenex, Inc. (0001300699) (Subject)
SC 13G/A - Athenex, Inc. (0001300699) (Subject)
SC 13G/A - Athenex, Inc. (0001300699) (Subject)
SC 13G - Athenex, Inc. (0001300699) (Subject)
SC 13G/A - Athenex, Inc. (0001300699) (Subject)
SC 13G/A - Athenex, Inc. (0001300699) (Subject)
SC 13G/A - Athenex, Inc. (0001300699) (Subject)
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning
BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: 1-844-826-3033 International: 1-412-317-5185 Pass
Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 millionCash used in operating activities for 1H 2022 was reduced 42% over the prior yearPresented promising early Phase 1 clinical trial data for CD19 and GD2 CAR-NKT cell products at ASTCT/CIBMTR Tandem Meetings and ASGCT annual meeting in 2Q 2022, respectivelyMaintains full-year 2022 product revenue guidance range of 20-25% growth year-over-year Management to host conference call and webcast today at 8:00 a.m. EDT BUFFALO, N.Y.
BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2022 on Thursday, July 28, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: (855) 327-6837 International: (631) 891-4304 Passco
Reports 1Q product sales of $29.0M, up 42% year-over-year Encouraging interim update from ANCHOR study of KUR-502 presented at ASTCT with 60% overall response rate (ORR) and 6-month complete response (CR) rate of 29% in the NHL cohortAbstract for KUR-501 in GINAKIT2 study accepted at ASGCT; 25% (3/12) ORR with 2 out of 3 responses at dose level 4 (1x108 cells/m2)Corporate reorganization and cost savings initiatives well underway, demonstrated by 28% and 39% reduction in SG&A expenses and R&D expenses, respectively, over the prior year period Raising full-year 2022 product revenue guidance range to 20-25% growth from previous range of 15-20% growth compared to 2021Management to host conferenc
BUFFALO, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the first quarter 2022 on Tuesday, May 10, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: (855) 327-6837 International: (631) 891-4304 Passcode
Announces Strategic Pivot to Focus on Cell Therapy Programs Receives FDA Clearance for IND to Expand CD19 CAR-NKT ANCHOR to a Multi-center Study Implementing Significant Cost Reduction Plan Targeting >50% Reduction in Operating Expenses Plans to Extend Cash Runway in 2022 Through Monetization of Non-core Assets Consistent with Shift in Focus and Strategy Management to host conference call and webcast today at 4:30 p.m. ET BUFFALO, N.Y., March 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today p
BUFFALO, N.Y., March 14, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Wednesday, March 16, 2022. Athenex's management team will host a conference call and live audio webcast at 4:30 p.m. Eastern Time. Please note the call is being rescheduled from the previously announced date of March 15 at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fift
BUFFALO, N.Y., March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Tuesday, March 15, 2022. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: (877) 407-0784 International: (201) 689-8560 Passcode: 13726
Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M, up 9% year-over-year Company now expects full year product sales revenue in 2021 to decrease by 6-12% compared to 2020 Management to host conference call and webcast today at 10:00 a.m. ET BUFFALO, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update f
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX) ("Athenex" or the "Company"), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company's assets across its primary businesses: Athenex Pharmaceu
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on November 22, 2022, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's common stock, at
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major clinical efficacy or safety concerns were expressed BUFFALO, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from
BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex's total product sales in the third quarter of 2022. The Company will continue to focus on creating value by advancing its cell therapy pipeline as well as monetizing non-core assets. "The decision to exit the 503B sterile compounding business continues the strategy laid out earlier this year to divest non-core assets a
Shareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special meeting of stockholders (the "Special Meeting"), held as a virtual meeting on November 22, 2022. Athenex shareholders have approved all three proposals put before them today at the Special Meeting, including: (1) to effect an increase in the total number of authorized shares of common stock of the Compan
BUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its equity interests in its China subsidiaries, which primarily represent the Company's ownership of its active pharmaceutical ingredient (API) manufacturing business in China, to Chongqing Comfort Pharmaceutical Inc. (Chongqing Comfort). Chongqing Comfort was assigned the rights and obligations under the Equity Purchase Agreement (Agreement) entered into in July 2022 by TiHe Capital (Beijing) Co. Ltd, p
BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022. Dr. Johnson Lau, Chief Executive Officer of Athenex, and Dr. Dan Lang, President of Athenex Cell Therapy, will be participating in a fireside chat on Wednesday, November 30, 2022, beginning at 3:05pm Eastern Time. Athenex management will also be available for one-on-one investor meetings during t
BUFFALO, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that a Nasdaq Hearings Panel has granted the company's request for continued listing on The Nasdaq Stock Market, subject to the Company's satisfaction of the minimum $1.00 bid price requirement by March 14, 2023. To evidence compliance with the minimum bid price requirement, the Company's common stock must close at or above $1.00 per share for a minimum of 10 (but generally not more than 20) consecutive business days by March 14
Bolstered balance sheet with $30 million public offering of common stock and warrantsNasdaq Hearing Panel grants Athenex's request for continued listingAthenex is in the final stages of closing the sale of the China API operationsI-SPY 2 study with Oral Paclitaxel expected to be completed by year-end 2022Phase 1 study updates for autologous KUR-501 (GD2 CAR-NKT cell therapy) in relapsed/refractory high-risk neuroblastoma (GINAKIT2) and allogeneic KUR-502 (CD19 CAR-NKT cell therapy) in relapsed/refractory B-cell malignancies (ANCHOR) expected by H1 2023Full-year 2022 product revenue guidance maintained at 20-25% growth year-over-year Management to host conference call and webcast today at 8:0
On Wednesday, 129 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Qualcomm (NASDAQ:QCOM) was the biggest company by market cap to set a new 52-week low. The smallest company in terms of market cap to set a new 52-week low was Athenex (NASDAQ:ATNX). QualTek Services (NASDAQ:QTEK)'s stock fell the most, as it traded down 38.7% to reach a new 52-week low. Delaware Investments (AMEX:VFL) saw the sharpest rebound, as shares ascended 0.02%, reversing after hiting a new 52-week low. Stocks dropping to new 52-week lows on Wednesday: Qualcomm (NASDAQ:QCOM) stock broke to a new 52-week low of $101.61 on Wednesday. Shares of the company traded down 1.82%.
On Monday, 85 stocks hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Bristol-Myers Squibb (NYSE:BMY) was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to hit a new 52-week low was Assure Hldgs (NASDAQ:IONM). Adamis Pharmaceuticals (NASDAQ:ADMP) was the biggest loser, trading down 6320.0% to reach its 52-week low. Greystone Housing Impact (NYSE:GHI) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. The following stocks set new 52-week lows on Monday: Bristol-Myers Squibb (NYSE:BMY) stock hit $65.14 on Monday morning, setting a new 52-week low for a change of down
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. The Dow traded up 0.07% to 33,325.35 while the NASDAQ rose 0.62% to 12,360.60. The S&P 500, also rose, gaining, 0.27% to 4,135.07. Check This Out: Top 5 Materials Stocks That May Collapse This Month Leading and Lagging Sectors Materials shares rose by 0.5% on Monday. Meanwhile, top gainers in the sector included Trinseo PLC (NYSE:TSE), up 10%, and Ivanhoe Electric Inc. (NYSE:IE), up 10%. In trading on Monday, utilities shares fell 1.4%. Top Headline Tower Semiconductor Ltd (NASDAQ:TSEM) posted upbeat results for its first quarter. Tower Semiconductor reported a r
Gainers NeoGames S.A. (NASDAQ:NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 1847 Holdings LLC (NASDAQ:EFSH) gained 64.5% to $0.9050 after the company reported a 27.6% increase in revenue to $15.4 million and achieved profitability for the first quarter. Harbor Custom Development, Inc. (NASDAQ:HCDI) surged 49.5% to $8.97 following first-quarter results. WiSA Technologies, Inc. (NASDAQ:WISA) rose 47.4% to $2.33 after the company signed a Letter of Intent to acquire Comhear. WiSA expects acquisition to be accretive beginning in the fourth quarter and sees FY24 revenue of $10 million to $15 million. O
Gainers Eloxx Pharmaceuticals (NASDAQ:ELOX) stock rose 36.0% to $4.84 during Monday's regular session. Trading volume for Eloxx Pharmaceuticals's stock is 141.8K as of 13:30 EST. This is 58.9% of its average full-day volume over the last 100 days. The company's market cap stands at $10.4 million. Vaxart (NASDAQ:VXRT) stock rose 31.42% to $1.38. Trading volume for this security as of 13:30 EST is 5.1 million, which is 411.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $187.1 million. Sarepta Therapeutics (NASDAQ:SRPT) shares rose 28.1% to $153.98. Trading volume for this security as of 13:30 EST is 5.4 million, which is 336.0% o
U.S. stocks traded mixed midway through trading, with the Dow Jones trading slightly lower on Monday. The Dow traded down 0.03% to 33,290.69 while the NASDAQ rose 0.35% to 12,328.38. The S&P 500, also rose, gaining, 0.06% to 4,126.71. Check This Out: Top 5 Materials Stocks That May Collapse This Month Leading and Lagging Sectors Financials shares rose by 0.6% on Monday. Meanwhile, top gainers in the sector included Upstart Holdings, Inc. (NASDAQ:UPST), up 11%, and Yiren Digital Ltd. (NYSE:YRD), up 10%. In trading on Monday, utilities shares fell 1.6%. Top Headline The NY Empire State Manufacturing Index fell to -31.8 in May from 10.8 in the previous month, recording the lowest
On Sunday, Athenex Inc (NASDAQ:ATNX) and certain of its subsidiaries voluntarily filed for Chapter 11 proceedings. Athenex agreed with its lenders to move forward with an expedited sale process of its assets, the company said in a statement. The company has listed estimated assets and liabilities of around $100 million-$500 million, Reuters reported citing a filing with the U.S. Bankruptcy Court for the Southern District of Texas. The company said the assets would be sold across its primary businesses of Athenex Pharmaceutical Division (APD), Orascovery, and Cell Therapy, adding that it expects the expedited process to be completed by July 1, 2023. Athenex has sufficient resources to sup
Athenex Inc (NASDAQ:ATNX) shares are trading lower after the company announced it voluntarily filed Chapter 11 proceedings. What Else? Athenex says this expedited sale will enable the company to divest its assets and wind down the Athenex platform in an orderly fashion, while seeking to maximize value for its stakeholders. The company says it anticipates concluding the expedited sales process by July 1, with the Chapter 11 cases continuing thereafter to resolve claims. Meanwhile, Athenex says the company has also reached an agreement with its secured lenders, subject to court approval, for the consensual use of cash collateral. Athenex says this will enable the company to, among other t
Gainers Cumberland (NASDAQ:CPIX) stock rose 30.3% to $2.15 during Monday's pre-market session. The market value of their outstanding shares is at $30.9 million. As per the press release, Q1 earnings came out 4 days ago. Aligos Therapeutics (NASDAQ:ALGS) shares increased by 27.52% to $1.39. The market value of their outstanding shares is at $59.6 million. Sarepta Therapeutics (NASDAQ:SRPT) stock increased by 25.87% to $151.3. The company's market cap stands at $14.0 billion. CEL-SCI (AMEX:CVM) stock moved upwards by 15.41% to $2.77. The market value of their outstanding shares is at $123.4 million. As per the news, the Q2 earnings report came out yesterday. Cadrenal Therapeutics (NASDAQ: